Get the Stockscreener App
9.00
1.10%
-0.10
Pre-market:
9.00
Organon Co stock is traded at $9.00, with a volume of 3.67M.
It is down -1.10% in the last 24 hours and up +25.35% over the past month.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
See More
Previous Close:
$9.10
Open:
$9
24h Volume:
3.67M
Relative Volume:
0.55
Market Cap:
$2.34B
Revenue:
$6.28B
Net Income/Loss:
$700.00M
P/E Ratio:
3.343
EPS:
2.6922
Net Cash Flow:
$537.00M
1W Performance:
-4.86%
1M Performance:
+25.35%
6M Performance:
-11.85%
1Y Performance:
-44.65%
1-Day Range:
$8.86
$9.215
1-Week Range:
$8.86
$9.94
52-Week Range:
$6.18
$17.23
Organon Co Stock (OGN) Company Profile
Name
Organon Co
Sector
Industry
Phone
551-430-6000
Address
30 HUDSON STREET, JERSEY CITY
Compare OGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
9.00 | 2.37B | 6.28B | 700.00M | 537.00M | 2.6922 |
|
LLY
Lilly Eli Co
|
1,039.51 | 951.18B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
224.44 | 533.63B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
223.93 | 390.19B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
152.22 | 286.13B | 54.45B | 14.42B | 17.15B | 7.333 |
|
NVO
Novo Nordisk Adr
|
62.89 | 284.29B | 46.69B | 15.29B | 9.25B | 3.4329 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Underweight |
| Oct-27-25 | Downgrade | Piper Sandler | Overweight → Underweight |
| May-02-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-06-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-03-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-21-23 | Initiated | Barclays | Overweight |
| Mar-16-23 | Initiated | Raymond James | Outperform |
| Oct-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-06-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Initiated | Piper Sandler | Neutral |
| Sep-01-21 | Initiated | BofA Securities | Buy |
| Jul-22-21 | Initiated | Citigroup | Buy |
| Jun-15-21 | Initiated | JP Morgan | Neutral |
| Jun-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-10-21 | Initiated | Evercore ISI | Outperform |
View All
Organon Co Stock (OGN) Latest News
Organon (OGN) Stock Sinks As Market Gains: What You Should Know - sharewise.com
Organon & Co. (OGN) Stock Analysis: Navigating a Challenging Landscape with Strategic Potential - DirectorsTalk Interviews
Valuation Update: Is Organon Co subject to activist investor interest2025 Pullback Review & Fast Entry Momentum Alerts - baoquankhu1.vn
543,711 Shares in Organon & Co. $OGN Purchased by Sector Gamma AS - MarketBeat
Organon & Co (OGN) Is Quietly Moving – Is This ‘Boring’ Stock Actually a Game-Changer for Your - AD HOC NEWS
Sun Pharma Bid Puts Organon Valuation And Growth Prospects In Focus - Sahm
(OGN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Acquisition Speculation and Regulatory Approval Drive Organon Shares - AD HOC NEWS
Organon Lures Sun Pharma With Low Valuation & Global Reach—What’s Next? - Smartkarma
Organon gains on report of Sun Pharmaceutical interest - MSN
Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report - AOL.com
Sun Pharma again on the prowl in the US market for acquisitions - Fortune India
Sun Pharma Weighs Potential $10 Billion Bid for Organon; Shares See Volatility - Whalesbook
Sun Pharma is said to mull bid for women’s wellness firm Organon - BusinessLine
India’s biggest pharma firm said to mull bid for New York-listed Organon - MSN
India’s Biggest Pharma Firm Said to Mull Bid for New York-Listed Organon - Bloomberg
Organon (OGN) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Organon acquisition buzz brings Sun Pharma deal strategy back - MSN
Sun Pharma Receives Buy Rating with ₹2,100 Target Price Amid Organon Acquisition Plans - scanx.trade
Massachusetts Financial Services Co. MA Has $101.48 Million Stake in Organon & Co. $OGN - MarketBeat
Barclays Initiates Organon & Co(OGN.US) With Sell Rating, Announces Target Price $7.5 - 富途牛牛
Why Sun Pharma’s hefty bid for Organon has divided investors | Company Business News - Mint
Organon & Co. (NYSE:OGN) Trading Up 8.8%What's Next? - MarketBeat
Why Are Organon (OGN) Shares Soaring Today - Finviz
Organon Stock Surges After FDA Nod for Nexplanon Expansion - StocksToTrade
Organon Secures FDA Approval Extending NEXPLANON Use to Five Years - Yahoo Finance
Sun Pharmaceutical Makes Non-Binding Offer to Acquire Organon for $10B-$14B - Intellectia AI
Aug Breakouts: Is 60 Degrees Pharmaceuticals Inc. Equity Warrant attractive at current valuationMarket Risk Analysis & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Sun Pharmaceutical Evaluates Organon Acquisition to Scale US Business - Chemical Industry Digest
BRIEF—Sun Pharma clarifies $10 billion Organon acquisition report - The Pharma Letter
Sun Pharma places non-binding offer for US-based Organon in its boldest global bet ever - The Economic Times
Sun Pharma looks to rise in US with $10 billion Organon buy - The Economic Times
Organon announces U.S. FDA approved sNDA for Nexplanon - TipRanks
FDA expands use of Organon’s contraception implant up to 5 years - Medical Device Network
Sun Pharma says talk of $10bn Organon bid is 'speculative' - pharmaphorum
Sun Pharma terms $10 billion Organon acquisition reports 'speculative' - Business Standard
Sun Pharma terms $10-billion Organon buy report as 'speculative' - Moneycontrol
Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque - BioSpace
Sun Pharma tight-lipped over rumoured $10B deal for Organon - FirstWord Pharma
M&A News: India’s Sun Pharma Eyes $10B Bid for U.S.’ Organon - TipRanks
Sun Pharma clarifies $10 bn Organon acquisition report, calls it 'speculative in nature' - The Economic Times
Sun Pharmaceutical Industries Denies $10 Billion Organon Acquisition Rumors - scanx.trade
India’s Sun Pharma weighs $10 bln bid for US-listed Organon, ET reports By Investing.com - Investing.com South Africa
India’s Sun Pharma weighs $10 bln bid for US-listed Organon, ET reports - Investing.com
Sun Pharma Officially Denies $10 Billion Organon Acquisition Speculation - scanx.trade
Organon (OGN) Receives FDA Approval for Nexplanon Label Expansion to 5 Years - Intellectia AI
Organon wins FDA nod to expand use of Nexplanon birth control implant - Seeking Alpha
Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Exte - PharmiWeb.com
Birth control implant Nexplanon now approved to last 5 years in US - Stock Titan
Organon (OGN) Receives FDA Approval to Extend NEXPLANON Use to 5 Years - Intellectia AI
Organon (OGN) Receives FDA Approval for NEXPLANON Extended Use Up to 5 Years - Intellectia AI
Organon Co Stock (OGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
1.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):